

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:)	Filed Electronically on:
Raed, Al-Qawasmeh, et al.)	May 29, 2007
)	
Serial No. 10/525,690)	
)	
Filed: October 24, 2006)	
)	
For: 2, 4, 5- TRISUBSTITUTED)	
IMIDAZOLES AND THEIR USE AS)	
ANTI-MICROBIAL AGENTS)	
)	
Examiner: not yet assigned)	
)	
Group Art Unit: 1614)	
)	
Confirmation No.: 7654)	

**TRANSMITTAL OF
INFORMATION DISCLOSURE STATEMENT
AFTER APPLICATION FILING DATE**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

ENCLOSURES

Enclosed are the following:

- * A completed PTO form SB/08A which has one (1) page.
- * A copy of each foreign and non patent literature document listed in the enclosed form PTO/SB/08a and not previously provided to or by the PTO in this application.

FEE DETERMINATION

- * No fee is believed to be due because:

In accordance with 37 CFR §1.97(e), each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of this statement.

FEE PAYMENT

The following arrangements have been made to pay the fees calculated above:

- * No fee is believed to be due.

The Commissioner is hereby authorized to charge any additional fees which are presently required, or credit any overpayment, to Deposit Account No. 13-0017.

REQUEST FOR CONSIDERATION

This paper and enclosures are believed to be entitled to consideration under 37 C.F.R. § 1.97, based on the facts stated above. The Examiner is requested to initial both copies of the enclosed PTO-1449 (modified) and return one copy to the applicants to indicate consideration of the enclosed references.

Respectfully submitted,



Michael B. Harlin
Reg. No. 43,658
Attorney for applicants

Dated: May 29, 2007

McAndrews, Held & Malloy, Ltd.
34th Floor
500 West Madison Street
Chicago, IL 60661
(312) 775-8000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number		10525690
Filing Date		2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.	
Art Unit	1614	
Examiner Name	not yet assigned	
Attorney Docket Number	16526US01	

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3297710	B1	1967-01-10	Silversmith	
	2	4089747	B1	1978-05-16	Bruschi	
	3	4423046	B1	1983-12-27	Carlson	
	4	4466976	B1	1984-08-21	Klose et al.	
	5	4585771	B1	1986-04-29	Klose et al.	
	6	4705855	B1	1987-11-10	Desideri et al.	
	7	4721670	B1	1988-01-26	Osada et al.	
	8	4902705	B1	1990-02-20	Hirota et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10525690
Filing Date		2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.	
Art Unit	1614	
Examiner Name	not yet assigned	
Attorney Docket Number	16526US01	

9	4970226	B1	1990-11-13	Sun	
10	5011472	B1	1991-04-30	Aebischer	
11	5023252	B1	1991-06-11	Hsieh	
12	5024935	B1	1991-06-18	McClune	
13	5047318	B1	1991-09-10	Snyder	
14	5496702	B1	1996-03-05	Bishop	
15	5514550	B1	1996-05-07	Findlay	
16	5656644	B1	1997-08-12	Adams	
17	5686455	B1	1997-11-11	Adams	
18	5693589	B1	1997-12-02	Goswami	
19	5753687	B1	1998-05-19	Mjalli	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10525690
Filing Date		2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.	
Art Unit	1614	
Examiner Name	not yet assigned	
Attorney Docket Number	16526US01	

20	5916891	B1	1999-06-29	Adams	
21	5945418	B1	1999-08-31	Bemis	
22	6060216	B1	2000-05-09	Ichikawa	
23	6117609	B1	2000-09-12	Maeda	
24	6194441	B1	2001-02-27	Roberts	
25	6268370	B1	2001-07-31	Adams	
26	6288212	B1	2001-09-11	Hancock	
27	6521655	B1	2003-02-18	Beers	
28	3279918	B1	1966-10-18	Cassiers	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
-------------------	---------	--------------------	------------------------	------------------	---	--

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10525690
Filing Date		2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.	
Art Unit	1614	
Examiner Name	not yet assigned	
Attorney Docket Number	16526US01	

1	20040176601	A1	2004-09-09	Goulet	
---	-------------	----	------------	--------	--

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	CA1195325	CA	B1	1985-10-15	Klose Walter; Boettcher Irmgard		<input type="checkbox"/>
	2	JP2002275458	JP	A1	2002-09-25	Fukuoka Prefecture		<input type="checkbox"/>
	3	WO 0078761	WO		2000-12-28	SEPRACOR, Inc.		<input checked="" type="checkbox"/>
	4	WO 03004023	WO	A1	2003-01-16	Schering Aktiengesellschaft		<input type="checkbox"/>
	5	WO 9827065	WO	A1	1998-06-25	Ontogen Corp.		<input checked="" type="checkbox"/>
	6	CA 2351694	CA	A1	1993-07-22	SmithKline Beecham Corp.		<input checked="" type="checkbox"/>
	7	WO 0224680	WO	A1	2002-03-28	SmithKline Beecham P.L.C.		<input checked="" type="checkbox"/>
	8	WO 0126467	WO	A1	2001-04-19	Ontogen Corp.		<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10525690
Filing Date		2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.	
Art Unit	1614	
Examiner Name	not yet assigned	
Attorney Docket Number	16526US01	

9	WO 0059541	WO	A1	2000-03-03	Sankyo Company	<input type="checkbox"/>
10	WO 02083111	WO	A2	2002-10-24	Tanabe Seiyaku Co., Ltd	<input checked="" type="checkbox"/>
11	DE 3141063	DE	A1	1985-10-15	Schering AG	<input type="checkbox"/>
12	WO 9902155	WO	A1	1999-01-21	Ontogen Corp.	<input checked="" type="checkbox"/>
13	WO 0246168	WO	A1	2002-06-13	AstraZeneca AB	<input checked="" type="checkbox"/>
14	EP 165588	EP	A2	1985-12-27	Fuji Photo Film Co., Ltd	<input checked="" type="checkbox"/>
15	EP 0812829	EP	A1	1997-12-17	Ontogen Corporation	<input checked="" type="checkbox"/>
16	WO 0033836	WO	A1	2000-06-15	Ontogen Corporation	<input checked="" type="checkbox"/>
17	WO 9618626	WO	A1	1996-06-20	F. Hoffmann-La Roche AG	<input checked="" type="checkbox"/>
18	WO 9503297	WO	A1	1995-02-02	SmithKline Beecham Corp.	<input checked="" type="checkbox"/>
19	WO 9314061	WO	A1	1993-07-22	SmithKline Beecham Corp.	<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10525690
Filing Date		2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.	
Art Unit	1614	
Examiner Name	not yet assigned	
Attorney Docket Number	16526US01	

	20	WO 03087026	WO	A1	2003-10-23	F.Hoffmann-La Roche AG		<input checked="" type="checkbox"/>
	21	WO 09736587	WO	A1	1997-10-09	Merck & Co., Inc.		<input checked="" type="checkbox"/>
	22	WO 9827108	WO	A2	1998-08-25	Fujisawa Pharmaceutical Co., Ltd.		<input checked="" type="checkbox"/>
	23	WO 9901128	WO	A1	1999-01-14	Neurogen Corp.		<input checked="" type="checkbox"/>
	24	WO 9907701	WO	A1	1999-02-18	Sugen, Inc.		<input checked="" type="checkbox"/>
	25	WO 2004016086	WO	A2	2004-02-26	Lorus Therapeutics Inc.		<input checked="" type="checkbox"/>
	26	WO 2005047266	WO	A1	2005-05-26	Lorus Therapeutics Inc.		<input checked="" type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	JOHN LEWIS; Muscarine, imidazole, oxazole, thiazole and peptide alkaloids, and other miscellaneous alkaloids; Natural Product Reports; 1998; 15: 417-437; Royal Society of Chemistry; London, UK	<input checked="" type="checkbox"/>
	2	JOHN LEWIS; Muscarine, imidazole, oxazole, thiazole and peptide alkaloids, and other miscellaneous alkaloids; Natural Product Reports; 1998; 15: 371-395; Royal Society of Chemistry; London, UK	<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10525690
Filing Date		2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.	
Art Unit	1614	
Examiner Name	not yet assigned	
Attorney Docket Number	16526US01	

3	JOHN LEWIS; Miscellaneous alkaloids: Amaryllidaceae, Sceleritum, muscarine, imidazole, oxazole, peptide and other miscellaneous alkaloids; Natural Product Reports; 1999; 16: 389-416; Royal Society of Chemistry; London, UK	<input checked="" type="checkbox"/>
4	LoGRASSO et al; Kinetic Mechanism for p38 MAP Kinase; Biochemistry; 1997; 36: 10422-10427; American Chemical Society; Rahway, New Jersey, USA	<input checked="" type="checkbox"/>
5	LOW et al; Clinical Prevalence, Antimicrobial Susceptibility, and Geographic Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997-1999; Clinical Infectious Diseases; 2001; 32: S133-145; University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
6	McLAY et al; The Discovery of RPR 200765A, a p38 MAP Kinase Inhibitor Displaying a Good Oral Anti-Arthritic Efficacy; Bioorganic & Medicinal Chemistry; 2001; 9: 537-554; Elsevier Science Ltd; Amsterdam, The Netherlands	<input checked="" type="checkbox"/>
7	HAMISH R. MICHIE; The value of animal models in the development of new drugs for the treatment of the sepsis syndrome; Journal for Antimicrobial Chemotherapy; 1998; 41: 47-49; British Society for Antimicrobial Chemotherapy; Birmingham, UK	<input checked="" type="checkbox"/>
8	MICHAEL A. PFALLER, MD and WEN LIANG YU, MD; Antifungal Susceptibility Testing; Infectious Disease Clinics of North America; 2001; 15: 1227-145; Elsevier; Philadelphia, PA, USA	<input checked="" type="checkbox"/>
9	PFALLER et al; Antifungal Susceptibility Testing: Technical Advances and Potential Clinical Applications; Clinical Infectious Diseases; 1997; 24: 776-84; University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
10	SARSHAR et al.; Imidazole Libraries on Solid Support; Tetrahedron Letters; 1996; 37: 835-838; Elsevier Science Ltd.; London, UK	<input checked="" type="checkbox"/>
11	SHIBATA et al.; Therapeutic efficacy of J-111, 225, a novel trans-3, 5-disubstituted pyrrolidinylthio-1 methylcarbamate, against experimental murine systemic infections; Journal of Antimicrobial Chemotherapy; 2000; 45: 379-82; British Society for Antimicrobial Chemotherapy; Birmingham, UK	<input checked="" type="checkbox"/>
12	SIMOR et al.; 1999 Canada Communicable Disease Report; 25: 105-108	<input checked="" type="checkbox"/>
13	STEVE STERNBERG; The Emerging Fungal Threat; Science; 1994; 266: 1632-1634; American Association for the Advancement of Science; Washington, DC, USA	<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10525690
Filing Date	2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.
Art Unit	1614
Examiner Name	not yet assigned
Attorney Docket Number	16526US01

14	THALER et al.; Evaluation of Single-Drug and Combination Antifungal Therapy in an Experimental Model of Candidiasis in Rabbits with Prolonged Neutropenia; The Journal of Infectious Diseases; 1988; 158: 80-88; University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
15	TOTSUKA et al.; Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo; Journal of Antimicrobial Chemotherapy; 1999; 44: 455-460; The British Society for Antimicrobial Chemotherapy; Birmingham, UK	<input checked="" type="checkbox"/>
16	WALSH et al.; Effects of Preventive, Early, and Late Antifungal Chemotherapy with Fluconazole in Different Granulocytopenic Models of Experimental Disseminated Candidiasis; The Journal of Infectious Diseases; 1990; 161: 755-760; University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
17	YANKE et al.; A CD-1 mouse model of infection with Staphylococcus aureus: Influence of gender on infection with MRSA and MSSA isolates; Canada Journal of Microbiology; 2000; 46:920-926; NRC Research Press website	<input checked="" type="checkbox"/>
18	ZHANG et al; 2,4,5-Trisubstituted Imidazoles: Novel Nontoxic Modulators of P-glycoprotein Mediated Multidrug Resistance. Part 2; Bioorganic & Medicinal Chemistry Letters; 2000; 10: 2603-2605; Elsevier Science Ltd; Philadelphia, PA, USA	<input checked="" type="checkbox"/>
19	GHANNOUM et al; Susceptibility Testing of Fungi: Current Status of Correlation of In Vitro Data with Clinical Outcome; Journal of Clinical Microbiology; 1996; 34: 489-495; American Society for Microbiology; Washington, DC, USA	<input type="checkbox"/>
20	ANTOLINI et al; Analogues of 4,5-bis(3,5-Dichlorophenyl)-2-Trifluoromethyl-1H-Imidazole as Potential Antibacterial Agents; Bioorganic and Medicinal Chemistry Letters; April 1999; 9(7):1023-1028; Elsevier Science Ltd; Philadelphia, PA, USA	<input type="checkbox"/>
21	ISIKDAG et al; QSAR of Inhibitory Activities by 2,4,5-Trisubstituted Imidazole Derivatives on Tubifex Worms; Acta Pharmaceutica Turcica; 1995; 37(1):19-24;	<input checked="" type="checkbox"/>
22	B. KRIEG and G. MANECKE; Synthese und Halbleitereigenschaften arylsubstituierter Imidazole, Naturforsch; 1967; 22b: 132-141	<input type="checkbox"/>
23	ABEL-MEGUID et al.; An Orally Bioavailable HIV-1 Protease Inhibitor Containing an Imidazole-Derived Peptide Bond Replacement: Crystallographic and Pharmacokinetic Analysis; Biochemistry; 1994; 33:11671 - 11677; American Chemical Society	<input checked="" type="checkbox"/>
24	ADAMS et al; Pyrimidinylimidazole Inhibitors of p38: Cyclic N-1 Imidazole Substituents Enhance p38 Kinase Inhibition and Oral Activity; Bioorganic and Medicinal Chemistry Letters; 2001; 11:2867-2870; Elsevier Science Ltd; Philadelphia, PA, USA	<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10525690
Filing Date	2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.
Art Unit	1614
Examiner Name	not yet assigned
Attorney Docket Number	16526US01

25	ARROYO et al.; Therapy of Murine Aspergillosis with Amphotericin B in Combination with Rifampin or 5-Fluorocytosine; Antimicrobial Agents and Chemotherapy; 1977; pp. 21-25; American Society for Microbiology; Washington, DC, USA	<input checked="" type="checkbox"/>
26	XIU R. BU et al; A Novel Approach to Synthesis of Tricyanovinylthiophene for heterocyclic Imidazole Nonlinear Optical Chromophores; Tetrahedron Letters; 1996; 37: 7331-7334; Elsevier Science Ltd; London, UK	<input checked="" type="checkbox"/>
27	CHI, K.; Palladium Catalyst in DMSO For the Oxidation of Tolans to Benzils; Synthetic Communications; 1994; 24(15): 2119-2122; Marcel Dekker, Inc., now Taylor and Francis	<input checked="" type="checkbox"/>
28	CUENDA et al; Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38); The EMBO Journal; 1997; 16: 295-305; Oxford University Press; Oxford, UK	<input checked="" type="checkbox"/>
29	CUENDA et al; SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1; Federation of European Biochemical Societies Letters; 1995; 364: 229-33; Elsevier BV on behalf of Federation of European Biochemical Societies	<input checked="" type="checkbox"/>
30	DIEKEMA et al; Survey of Infections due to Staphylococcus Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999; Clinical Infectious Diseases; 2001; 32: S114-132; University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
31	EKWALL, BJORN; Screening of Toxic Compounds in Mammalian Cell Cultures; Annals New York Academy of Sciences; 1983; 407: 64-77; Blackwell Publishing	<input type="checkbox"/>
32	FISHCER et al; Dissociation Constants of the Conjugate Acids of Substituted Benzyl Phenyl Ketones and of Alkyl-substituted Benzophenones; Journal of American Chemical Society; 1961; 83: 4208-4210; American Chemical Society; Washington, DC, USA	<input checked="" type="checkbox"/>
33	GALES et al; Characterization of Pseudomonas aeruginosa Isolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997-1999; Clinical Infectious Diseases; 2001; 32:S146-155; Infectious Disease Society of America; The University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
34	GOTO et al; Improved efficacy with nonsimultaneous administration of netilmicin and minocycline against methicillin-resistant Staphylococcus aureus in in vitro and in vivo models; International Journal of Antimicrobial Agents; 1999; 11:39-46; International Society of Chemotherapy; Elsevier Science B.V.; United Kingdom	<input checked="" type="checkbox"/>
35	GUIJARRO et al; The Reaction of Active Zinc with Organic Bromides; Journal of American Chemical Society; 1999; 121, 4155-4157; American Chemical Society; Washington, DC, USA	<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10525690
Filing Date	2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.
Art Unit	1614
Examiner Name	not yet assigned
Attorney Docket Number	16526US01

36	HEERDING et al; 1,4 Disubstituted Imidazoles are Potential Antibacterial Agents Functioning as Inhibitors of Enoyl Acyl Carrier Protein Reductase (FabI); Biorganic and Medicinal Chemistry Letters; 2001, 11:2061-2065; Elsevier Science Ltd; Philadelphia, PA, USA	<input checked="" type="checkbox"/>
37	HOBAN et al; Worldwide Prevalence of Antimicrobial Resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999; Clinical Infectious Diseases; 2001: 32:S81-93; Infectious Disease Society of America; The University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
38	HUESCA et al; Adhesion and Virulence Properties of Epidemic Canadian Methicillin-Resistant Staphylococcus aureus Strain 1: Identification of Novel Adhesion Functions Associated with Plasmin-Sensitive Surface Protein; The Journal of Infectious Disease; 2002; Infectious Diseases Society of America; The University of Chicago Press; Chicago, IL, USA	<input checked="" type="checkbox"/>
39	IWAHI et al; Virulence of Escherichia Coli in Ascending Urinary-Tract Infection in Mice; Journal of Medical Microbiology; 1982; 15:303-316; The Society for General Microbiology; HighWire Press	<input checked="" type="checkbox"/>
40	SARSHAR et al; 2,4,5-Trisubstituted Imidazoles: Novel Nontoxic Modulators of P-glycoprotein Mediated Multidrug Resistance. Part 1; Biorganic and Medicinal Chemistry Letters; 2000; 10:2599-2601; Elsevier Science Ltd; Philadelphia, PA, USA	<input checked="" type="checkbox"/>
41	ARMESTO et al; A New Site Selective Synthesis of Benzoin Esters, Synthesis of Symmetrically and Unsymmetrically Substituted Benzils; Synthesis; 1988; 799-801	<input checked="" type="checkbox"/>
42	TANASEICHUK et al.; Uch. Zap., Mord. Univ. (1971), No. 81, 95-7 (From: Ref. Zh., Khim. 1972, Abstr. No. 12zh318 (English abstract)	<input type="checkbox"/>
43	BHADURI et al.; Potential Antifertility Agents: Syntheses of 2,4,5-Substituted Imidazoles; Indian Journal of Chemistry; 1966; 4(9): 419-20; NISCAIR; New Delhi, India	<input checked="" type="checkbox"/>
44	Database WPI; Section Ch. Week 199940, Derwent Publications Ltd., London, GB, Class B02, AN 1999-474062 (XP002268773) & JP 11199582 (english abstract) A (Sagami Chem Res Cent), July 27, 1999	<input checked="" type="checkbox"/>
45	LECHNER et al.; Differential Production of TNK by Kupffer cells after phagocytosis of E. coli and C. albicans; American Journal of Physiology; 1994; 10:1-8; American Physiological Society	<input checked="" type="checkbox"/>
46	KLOSE et al; The Suckling Mouse Model of Cholera; Trends in Microbiology; 2000; 8:189-91; Elsevier Science Ltd	<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10525690
Filing Date	2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.
Art Unit	1614
Examiner Name	not yet assigned
Attorney Docket Number	16526US01

47	LEE et al; A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis; Nature; 1994; 327: 739-745	<input checked="" type="checkbox"/>
----	--	-------------------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10525690
Filing Date	2006-10-24
First Named Inventor	Raed, Al-Qawasmeh et al.
Art Unit	1614
Examiner Name	not yet assigned
Attorney Docket Number	16526US01

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☒ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).


OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2007-05-29
Name/Print	Michael B. Harlin	Registration Number	43,658

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.